Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Neoplasms 1Meningeal Carcinomatosis 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Radiosurgery 27Radiotherapy 17Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14Bevacizumab 13Pemetrexed 10Carboplatin 10pembrolizumab 9Gefitinib 9osimertinib 8icotinib 7Temozolomide 7Nivolumab 6Specimen Handling 5Paclitaxel 5Spermine Synthase 4Mental Status and Dementia Tests 4Ipilimumab 4Drug Therapy 4Cisplatin 4atezolizumab 3alectinib 3aflutinib 3Radiation 3Immunotherapy 3Fluorodeoxyglucose F18 3regorafenib 2paclitaxel-Angiopep-2 conjugate 2motexafin gadolinium 2epothilone B 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Brain Neoplasms × XL647 × Thoracic × Clear all
NCT02616393 2022-03-16

Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases

Kadmon Corporation, LLC

Phase 2 Completed
36 enrolled 22 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡